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Abstract—Adverse drug reaction (ADR) is widely 
concerned for public health issue. In this study we 
propose an original approach to detect the ADRs using 
feature matrix and feature selection. The experiments 
are carried out on the drug Pioglitazone. Major side 
effects for the drug are detected and better performance 
is achieved compared to other computerized methods. 
The detected ADRs are based on the computerized 
method, further investigation is needed.
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I. INTRODUCTION 
Adverse drug reaction (ADR) is widely concerned for 
public health issue. ADRs are one of most common causes to 
withdraw some drugs from market [ 1 ]. Now two major 
methods for detecting ADRs are spontaneous reporting 
system (SRS) [2,3], and prescription event monitoring (PEM) 
[4 ,5]. The World Health Organization (WHO) defines a 
signal in pharmacovigilance as “any reported information on 
a possible causal relationship between an adverse event and a 
drug, the relationship being unknown or incompletely 
documented previously”[ 6 ]. For spontaneous reporting 
system, many machine learning methods are used to detect 
ADRs, such as Bayesian confidence propagation neural 
network (BCPNN) [7], decision support method [8], genetic 
algorithm [9], knowledge based approach [10], etc. One 
limitation is the reporting mechanism to submit ADR reports 
[8], which has serious underreporting and is not able to 
accurately quantify the corresponding risk. Another 
limitation is hard to detect ADRs with small number of 
occurrences of each drug-event association in the database.  
In this paper we propose feature selection approach to 
detect ADRs from The Health Improvement Network (THIN) 
database. First feature matrix, which represents the medical 
events for the patients before and after taking drugs, is 
created by linking patients’ prescriptions and corresponding 
medical events together. Then significant features are 
selected based on feature selection methods, comparing the 
feature matrix before patients take drugs with one after 
patients take drugs. Finally the significant ADRs can be 
detected from thousands of medical events based on 
corresponding features. Experiments are carried out on the 
drug Pioglitazone. Good performance is achieved.  
II. FEATURE MATRIX AND FEATURE SELECTION
A. The Extraction of Feature Matrix 
 To detect the ADRs of drugs, first feature matrix is 
extracted from THIN database, which describes the medical 
events that patients occur before or after taking drugs. Then 
feature selection method of Student’s t-test is performed to 
select the significant features from feature matrix containing 
thousands of medical events.  Figure 1 shows the process to 
detect the ADRs using feature matrix. Feature matrix A
describes the medical events for each patient during 60 days 
before they take drugs. Feature matrix B  reflects the 
medical events during 60 days after patients take drugs. In 
order to reduce the effect of the small events, and save the 
computation time and space, we set 100 patients as a group. 
Matrix X  and Y  are feature matrix after patients are 
divided into groups. 
Figure 1. The process to detect ADRs. Matrix A  and B  are 
feature matrix before patients take drugs or after patients 
take drugs. The time period of observation is set to 60 days. 
Matrix X  and Y  are feature matrix after patients are 
divided into groups. We set 100 patients as one group. 
B. Medical Events and Readcodes 
Medical events or symptoms are represented by medical 
codes or Readcodes. There are 103387 types of medical 
events in “Readcodes” database. The Read Codes used in 
general practice (GP), were invented and developed by Dr 
James Read in 1982. The NHS (National Health Service) has 
expanded the codes to cover all areas of clinical practice. 
The code is hierarchical from left to right or from level 1 to 
level 5. It means that it gives more detailed information from 
level 1 to level 5.  Table 1 shows the medical symptoms 
based on Readcodes at level 3 and at level 5.  ‘Other soft 
tissue disorders’ is general term using Readcodes at level 3.  
‘Foot pain’, ‘Heel pain’, etc., give more details using 
Readcodes at level 5. 
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C. Feature Selection Based on Student’s t-test 
Feature extraction and feature selection are widely used 
in biomedical data processing [11-18]. In our research we 
use Student’s t-test [19] feature selection method to detect 
the significant ADRs from thousands of medical events. 
Student’s t-test is a kind of statistical hypothesis test based 
on a normal distribution, and is used to measure the 
difference between two kinds of samples. 
TABLE I. MEDICAL EVENTS BASED ON READCODES AT LEVEL 3 AND 
LEVEL 5. 
 Level Readcodes Medical events 
 Level 3   N24..00  Other soft tissue disorders 
  N245.16  Leg pain  
  N245111  Toe pain  
  N245.13   Foot pain  
  N245700  Shoulder pain  
Muscle 
pain
Level 5 
  N245.15   Heel pain  
D. Other Parameters 
The variable of ratio 1R is defined to evaluate significant 
changes of the medical events, using ratio of the patient 
number after taking the drug to one before taking the drug.  
The variable 2R  represents the ratio of patient number after 
taking the drug to the number of whole population having 
one particular medical symptom. 
The ratio variables 1R and 2R  are defined as follows: 
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where BN and AN  represent the numbers of patients 
before or after they take drugs for having one particular 
medical event respectively. The variable N  represents the 
number of whole population who take drugs. 
III. EXPERIMENTS AND RESULTS
Pioglitazone [20] is a prescription drug of the class 
thiazolidinedione (TZD) with hypoglycemic 
(antihyperglycemic, antidiabetic) action to treat diabetes.  
 On July 30, 2007 an Advisory Committee of the Food 
and Drug Administration concluded that the use of 
rosiglitazone for the treatment of type 2 diabetes was 
associated with a greater risk of "myocardial ischemic 
events".   On June 9, 2011 the French Agency for the Safety 
of Health Products decided to withdraw pioglitazone in 
regards to high risk of bladder cancer. On June 10, 2011 
Germany's Federal Institute for Drugs and Medical Devices 
also advised doctors not to prescribe the medication until 
further investigation of the cancer risk had been conducted. 
Pioglitazone [21] has the side effects: severe allergic 
reactions (rash; hives; itching; difficulty breathing; tightness 
in the chest; swelling of the mouth, face, lips, or tongue); 
blurred vision or other vision changes; swelling of the hands, 
ankles, or feet; symptoms of heart failure (shortness of breath; 
sudden, unexplained weight gain); symptoms of liver 
problems (dark urine; stomach pain; unexplained nausea, 
vomiting, or loss of appetite; yellowing of the skin or eyes); 
symptoms of low blood sugar (anxiety; chills, increased 
hunger, headache; increased dizziness or drowsiness; 
tremors); unusual bone pain; unusual tiredness or weakness, 
etc.
9093 patients from half of 475GP data in THIN database 
are taking Pioglitazone, and 11342 medical events are 
obtained based on Readcodes at level 1-5. After grouping 
them, 90x113412 feature matrix is obtained. For Readcodes 
at level 1-3, 90x2545 feature matrix is obtained.  
Table 2 shows the top 30 detected results in ascending 
order of p value of Student’s t-test, using Readcodes at level 
1-5 and at level 1-3. The detected results are using p value 
less than 0.05, which represent the significant change after 
patients take the drug.  Table 3 shows the results in 
descending order of the ratio of the number of patients after 
taking the drug to one before taking the drug. Table 4 shows 
the potential ADRs related to cancer for Pioglitazone based 
on p value of Student’s t-test. Our detected results are 
consistent with the published side effects [20, 21]. Good 
performance is achieved.  
MUTARA and HUNT [22ˈ23] based on Unexpected 
Temporal Association Rule  are proposed to signal 
unexpected and infrequent patterns characteristic of ADRs, 
using The Queensland Linked Data Set (QLDS). They 
indicated that “HUNT can reliably shortlist statistically 
significantly more ADRs than MUTARA”. For the drug of 
Atorvastatin, HUNT detects 4 ADRs of ‘urinary tract 
infection’, ‘stomach ulcer’, ‘diarrhoea’, and ‘bronchitis’ 
from top 20 results based on 13712 patient records, and only 
obtains 30% accuracy [23]. The major side effects of 
Atorvastatin, which are ‘muscle pain’, ‘muscle weakness’, 
and other musculoskeletal events, are not detected. Table 5 
shows the performance of HUNT and MUTARA.  
TABLE Vˊ THE ACCURACY OF HUNT AND MUTARA [23]. 
               Experimental settings  Signalling accuracy  
  Drug Patients HUNT MUTARA
Older female  0.30 0.20 
Older male  0.30 0.20 Atorvastatin
All patients (13712) 0.30 0.20 
IV. CONCLUSIONS
In this study we propose a novel method to successfully 
detect the ADRs using feature matrix and feature selection. 
A feature matrix, which characterizes the medical events 
before patients take drugs or after patients take drugs, is 
created from THIN database. The feature selection method 
of Student’s t-test is used to detect the significant features 
from thousands of medical events. The significant ADRs, 
which are corresponding to significant features, are detected. 
Experiments are performed on the drug Pioglitazone. 
Compared to other computerized method, our proposed 
method achieves good performance.  
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TABLE II. THE POTENTIAL TOP 30 ADRS FOR PIOGLITAZONE BASED ON P VALUE OF STUDENT’S T-TEST.
Rank Readcodes Medical events NB NA R1 R2 
1  1Z12.00           Chronic kidney disease stage 3     133     623    4.68      6.85 
  2  182..00                               Chest pain     124     485    3.91      5.33 
  3  1M10.00                                Knee pain     141     546    3.87      6.00 
  4  N245.17                            Shoulder pain     142     501    3.53      5.51 
  5  1D14.00                              C/O: a rash      98     403    4.11      4.43 
  6  N131.00               Cervicalgia - pain in neck      64     328    5.13      3.61 
  7  M03z000                           Cellulitis NOS      61     277    4.54      3.05 
  8  16C6.00          Back pain without radiation NOS      76     327    4.30      3.60 
  9  1C9..00                      Sore throat symptom      46     259    5.63      2.85 
 10  N143.00                                 Sciatica      37     221    5.97      2.43 
 11  171..00                                    Cough     196     765    3.90      8.41 
 12  F420.00                     Diabetic retinopathy      45     264    5.87      2.90 
 13  1B5..11                        Dizziness symptom      61     286    4.69      3.15 
 14  H01..00                          Acute sinusitis      39     193    4.95      2.12 
 15  K190.00 Urinary tract infection, site not specified      65     268    4.12      2.95 
 16  D00..00                 Iron deficiency anaemias      38     205    5.39      2.25 
 17  E227311                     Erectile dysfunction      81     264    3.26      2.90 
 18  1B8..00                             Eye symptoms      30     169    5.63      1.86 
 19  H06z000                      Chest infection NOS     130     479    3.68      5.27 
 20  1739.00                      Shortness of breath      54     278    5.15      3.06 
 21  F46..00                                 Cataract      31     154    4.97      1.69 
 22  N245200                              Pain in leg      29     194    6.69      2.13 
 23  F4C0.00                     Acute conjunctivitis      45     205    4.56      2.25 
 24  M15y100                               Intertrigo      18     114    6.33      1.25 
 25  C380.00                                  Obesity      66     275    4.17      3.02 
 26  N142.11                            Low back pain      83     357    4.30      3.93 
 27  183..00                                   Oedema      46     273    5.93      3.00 
 28  N094K12                                 Hip pain      48     215    4.48      2.36 
 29  1A55.00                                  Dysuria      50     197    3.94      2.17 
Level  
1-5
 30  C112.00                Hypoglycaemia unspecified      25     176    7.04      1.94 

1  171..00                                    Cough     419    1501    3.58     16.51 
  2  N24..00              Other soft tissue disorders     445    1675    3.76     18.42 
  3  H06..00       Acute bronchitis and bronchiolitis     308    1124    3.65     12.36 
  4  183..00                                   Oedema     133     694    5.22      7.63 
  5  N21..00 Peripheral enthesopathies and allied syndromes     150     652    4.35      7.17 
  6  16C..00                         Backache symptom     175     708    4.05      7.79 
  7  1B1..00                 General nervous symptoms     189     711    3.76      7.82 
  8  173..00                           Breathlessness     221     878    3.97      9.66 
  9  1D1..00                   C/O: a general symptom     202     771    3.82      8.48 
 10  H05..00 Other acute upper respiratory infections     142     634    4.46      6.97 
 11  1M1..00                       Pain in lower limb     171     675    3.95      7.42 
 12  182..00                               Chest pain     166     627    3.78      6.90 
 13  N14..00     Other and unspecified back disorders     139     650    4.68      7.15 
 14  1C9..00                      Sore throat symptom      51     323    6.33      3.55 
 15  N05..00      Osteoarthritis and allied disorders     109     488    4.48      5.37 
 16  M03..00             Other cellulitis and abscess      92     387    4.21      4.26 
 17  K19..00 Other urethral and urinary tract disorders     107     482    4.50      5.30 
 18  1B8..00                             Eye symptoms      82     396    4.83      4.35 
 19  F42..00                  Other retinal disorders     195     850    4.36      9.35 
 20  N09..00    Other and unspecified joint disorders     188     744    3.96      8.18 
 21  N13..00                 Other cervical disorders      66     352    5.33      3.87 
 22  F50..00                Disorders of external ear     114     449    3.94      4.94 
 23  F4C..00                 Disorders of conjunctiva      71     334    4.70      3.67 
 24  1Z1..00                 Chronic renal impairment     220     838    3.81      9.22 
 25  G57..00                     Cardiac dysrhythmias      30     165    5.50      1.81 
 26  19F..00                       Diarrhoea symptoms     202     524    2.59      5.76 
 27  1C1..00                         Hearing symptoms      42     240    5.71      2.64 
 28  1B5..00                   Incoordination symptom      74     349    4.72      3.84 
 29  D00..00                 Iron deficiency anaemias      52     271    5.21      2.98 
Level  
1-3
 30  168..00                        Tiredness symptom     106     409    3.86      4.50 
Variable NB and NA represent the numbers of patients before or after they take drugs for having one particular medical event.  Variable  R1 represents the ratio of 
the numbers of patients after taking drugs to the numbers of patients before taking drugs. Variable  R2 represents the ratio of the numbers of patients after taking 
drugs to the number of the whole population. 
TABLE III. THE POTENTIAL TOP 30 ADRS FOR PIOGLITAZONE BASED ON DESCENDING ORDER OF R1 VALUE.
 Rank Readcodes Medical events NB NA R1 R2 
 1  16J..00                                 Swelling       1      43   43.00      0.47 
  2  1C84.00                    C/O - post nasal drip       1      35   35.00      0.38 
  3  J15..00                 Gastritis and duodenitis       1      29   29.00      0.32 
  4  1B5..13                         Unsteady symptom       1      28   28.00      0.31 
  5  A07y000                    Viral gastroenteritis       1      28   28.00      0.31 
  6  G30..00              Acute myocardial infarction       1      27   27.00      0.30 
  7  172..12                    Haemoptysis - symptom       1      27   27.00      0.30 
  8  Fy03.11                 Obstructive sleep apnoea       1      27   27.00      0.30 
  9  F4F2.00                                 Epiphora       1      23   23.00      0.25 
 10  SK17200                       Other ankle injury       1      22   22.00      0.24 
 11  1C6..00                       Nose bleed symptom       0      20   20.00      0.22 
 12  N211.00 Rotator cuff shoulder syndrome and allied disorders       1      20   20.00      0.22 
 13  K197200                   Microscopic haematuria       1      20   20.00      0.22 
 14  C294300                          Iron deficiency       1      20   20.00      0.22 
 15  M101.12                       Seborrhoeic eczema       1      19   19.00      0.21 
 16  AB0..12                                 Ringworm       0      18   18.00      0.20 
 17  F4C1411                  Allergic conjunctivitis       2      36   18.00      0.40 
 18  G30..15         MI - acute myocardial infarction       0      17   17.00      0.19 
 19  G87..00                              Hypotension       2      32   16.00      0.35 
 20  Eu01.00                     [X]Vascular dementia       0      16   16.00      0.18 
 21  1A24.00                      Stress incontinence       0      16   16.00      0.18 
 22  173C.12                                    SOBOE       2      32   16.00      0.35 
 23  N212200                  Subacromial impingement       1      16   16.00      0.18 
 24  F425.00 Degeneration of macula and posterior pole       0      16   16.00      0.18 
 25  G573200           Paroxysmal atrial fibrillation       0      16   16.00      0.18 
 26  1B87.00                        Has watering eyes       0      16   16.00      0.18 
 27  F310.00                    Bell's (facial) palsy       1      16   16.00      0.18 
 28  N245100                                Foot pain       1      16   16.00      0.18 
 29  C10FJ00 Insulin treated Type 2 diabetes mellitus       4      61   15.25      0.67 
Level  
1-5
 30  19FZ.11            Diarrhoea & vomiting, symptom       3      45   15.00      0.49 
 1  N12..00            Intervertebral disc disorders       1      24   24.00      0.26 
  2  C29..00           Other nutritional deficiencies       1      21   21.00      0.23 
  3  SD9..00 Superficial injuries of multiple and unspecified sites       1      19   19.00      0.21 
  4  B22..00 Malignant neoplasm of trachea, bronchus and lung       1      18   18.00      0.20 
  5  1BD..00                         Harmful thoughts       1      18   18.00      0.20 
  6  J07..00                  Salivary gland diseases       1      16   16.00      0.18 
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  7  S33..00             Fracture of tibia and fibula       1      16   16.00      0.18 
  8  F31..00                   Facial nerve disorders       1      16   16.00      0.18 
  9  C28..00                     Vitamin D deficiency       1      16   16.00      0.18 
 10  159..00           H/O:gynaecological problem NOS       1      15   15.00      0.16 
 11  1C2..00                        Tinnitus symptoms       1      15   15.00      0.16 
 12  172..00            Blood in sputum - haemoptysis       2      29   14.50      0.32 
 13  N35..00              Acquired deformities of toe       1      14   14.00      0.15 
 14  1BO..00                              Mood swings       1      14   14.00      0.15 
 15  SL...15                         Overdose of drug       0      13   13.00      0.14 
 16  Fy0..00                          Sleep disorders       4      50   12.50      0.55 
 17  H2z..00               Pneumonia or influenza NOS       0      12   12.00      0.13 
 18  Eu5..00 [X]Behav synd assoc with physiolgcl disturb + physical fctrs       0      12   12.00      0.13 
 19  1J6..00                  Suspected heart disease       1      12   12.00      0.13 
 20  D0...00                      Deficiency anaemias       1      12   12.00      0.13 
 21  SH...00                                    Burns       0      11   11.00      0.12 
 22  SN4..00              Other external effect cause       0      11   11.00      0.12 
 23  SD6..00 Superficial injury of lower limb, excluding foot       1      11   11.00      0.12 
 24  B49..00    Malignant neoplasm of urinary bladder       1      11   11.00      0.12 
 25  S89..00 Other open wounds of other sites, excluding limbs       1      11   11.00      0.12 
 26  TJC..00 Adverse reaction to cardiovascular system drugs       0      11   11.00      0.12 
 27  H1y..00 Other specified diseases of upper respiratory tract       4      43   10.75      0.47 
 28  F30..00               Trigeminal nerve disorders       2      21   10.50      0.23 
 29  SE3..00                    Contusion, upper limb       2      20   10.00      0.22 
Level 
 1-3 
 30  N36..00            Other acquired limb deformity       0      10   10.00      0.11 
TABLE IV. THE POTENTIAL ADRS RELATED TO CANCER FOR PIOGLITAZONE BASED ON P VALUE OF STUDENT’S T-TEST.
Rank Readcodes Medical events NB NA R1 R2 
 1  B76..00                  Benign neoplasm of skin      15      73    4.87      0.80 
  2  B22..00 Malignant neoplasm of trachea, bronchus and lung       1      18   18.00      0.20 
  3  B33..00         Other malignant neoplasm of skin      17      48    2.82      0.53 
  4  B34..00      Malignant neoplasm of female breast       3      22    7.33      0.24 
  5  BB2..00 [M]Papillary and squamous cell neoplasms       4      21    5.25      0.23 
  6  BB5..00          [M]Adenomas and adenocarcinomas       7      24    3.43      0.26 
  7  B49..00    Malignant neoplasm of urinary bladder       1      11   11.00      0.12 
  8  B46..00           Malignant neoplasm of prostate       4      22    5.50      0.24 
  9  B8...00                        Carcinoma in situ       2      13    6.50      0.14 
 10  B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus       1       9    9.00      0.10 
 11  B13..00              Malignant neoplasm of colon       3      14    4.67      0.15 
 12  B59..00   Malignant neoplasm of unspecified site       0       5    5.00      0.05 
 13  B83..00 Carcinoma in situ of breast and genitourinary system       1       7    7.00      0.08 
 14  B71..00 Benign neoplasm of other parts of digestive system       3      12    4.00      0.13 
 15  B51..00              Malignant neoplasm of brain       0       4    4.00      0.04 
 16  B430200 Malignant neoplasm of endometrium of corpus uteri       0       3    3.00      0.03 
 17  B80..00    Carcinoma in situ of digestive organs       0       3    3.00      0.03 
 18  B17..00           Malignant neoplasm of pancreas       1       5    5.00      0.05 
 19  B58..00 Secondary malignant neoplasm of other specified sites       1       5    5.00      0.05 
 20  BBH..00                  [M]Myxomatous neoplasms       0       2    2.00      0.02 
 21  B21..00             Malignant neoplasm of larynx       0       2    2.00      0.02 
 22  B11..00            Malignant neoplasm of stomach       0       2    2.00      0.02 
 23  BB4..00 [M]Transitional cell papillomas and carcinomas       0       2    2.00      0.02 
 24  BBG..00                 [M]Fibromatous neoplasms       0       2    2.00      0.02 
 25  B10..00         Malignant neoplasm of oesophagus       0       2    2.00      0.02 
 26  B82..00                Carcinoma in situ of skin       0       2    2.00      0.02 
 27  B53..00      Malignant neoplasm of thyroid gland       0       2    2.00      0.02 
 28  BB1J.00              [M]Small cell carcinoma NOS       0       2    2.00      0.02 
 29  B7E..00                  Benign neoplasms of eye       1       4    4.00      0.04 
 30  BB3..00                  [M]Basal cell neoplasms       2       5    2.50      0.05 
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